

Edited by  
**J. D. Williams and A. M. Geddes**

---

# **CHEMOTHERAPY**

---

Volume 3

**Special Problems  
in Chemotherapy**

# CHEMOTHERAPY

## Volume 3 Special Problems in Chemotherapy

Edited by  
**J.D. Williams**  
*The London Hospital Medical College  
London, U.K.*

and  
**A.M. Geddes**  
*East Birmingham Hospital  
Birmingham, U.K.*

Plenum Press · New York and London

International Congress of Chemotherapy, 9th, London, 1975.  
Special problems in chemotherapy.

(Chemotherapy; v. 3)

1. Chemotherapy — Congresses. 2. Antitubercular agents — Congresses. 3. Genito-urinary organs — Diseases — Chemotherapy — Congresses. 4. Drugs resistance in micro-organisms — Congresses. 5. Antiseptic medication — Congresses. I. Williams, John David, M.D. II. Geddes, Alexander McIntosh. III. Title. IV. Series.

RM260.2.C45

vol. 3

615'.58s

[615'.58]

76-1947

ISBN 0-306-38223-7

Proceedings of the Ninth International Congress of Chemotherapy  
held in London, July, 1975 will be published in eight volumes,  
of which this is volume three.

©1976 Plenum Press, New York

A Division of Plenum Publishing Corporation  
227 West 17th Street, New York, N.Y. 10011

United Kingdom edition published by Plenum Press, London

A Division of Plenum Publishing Company, Ltd.

Davis House (4th Floor), 8 Scrubs Lane, Harlesden, London, MW10 6SE, England

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted,  
in any form or by any means, electronic, mechanical, photocopying, microfilming,  
recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

# **CHEMOTHERAPY**

Volume 3  
Special Problems  
in Chemotherapy

# CHEMOTHERAPY

- Volume 1 Clinical Aspects of Infections**  
Prophylaxis; life-threatening infections; infection in leukaemia;  
surgical infection; anaerobic infection; respiratory and urinary  
tract infections; amikacin.
- Volume 2 Laboratory Aspects of Infections**  
Sensitivity testing; assay methods; animal models of infection;  
sisomycin; tobramycin.
- Volume 3 Special Problems in Chemotherapy**  
Tuberculosis; genital tract infections; antibiotic resistance and  
mode of action; topical chemotherapy and antiseptics.
- Volume 4 Pharmacology of Antibiotics**  
Tissue concentrations; pharmacokinetics; untoward effects of antibiotics.
- Volume 5 Penicillins and Cephalosporins**  
Penicillins and cephalosporins; betalactamases; new agents.
- Volume 6 Parasites, Fungi, and Viruses**  
Parasitic infections; fungal infections; chemotherapy of viruses;  
co-trimoxazole.
- Volume 7 Cancer Chemotherapy I**  
Symposia — new drugs and approaches; cell and pharmacokinetics;  
potentiators of radiotherapy; in vitro screening systems;  
immunological aspects.
- Volume 8 Cancer Chemotherapy II**  
Free papers — new drugs and approaches; cell and pharmacokinetics;  
mechanisms of action; new analogues; cancer chemotherapy of specific organs.

# CHEMOTHERAPY

Proceedings of the  
9th International Congress of Chemotherapy  
held in London, July, 1975

## *Editorial Committee*

K. Hellmann, *Chairman* (Anticancer)  
*Imperial Cancer Research Fund, London.*

A. M. Geddes (Antimicrobial)  
*East Birmingham Hospital.*

J. D. Williams (Antimicrobial)  
*The London Hospital Medical College.*

## *Congress Organising Committee*

W. Brumfitt  
K. Hellmann  
K.D. Bagshawe  
H. Smith  
E.J. Stokes  
F. Wrigley  
J.D. Williams

I. Phillips  
M.R.W. Brown  
D.G. James  
C. Stuart-Harris  
R.G. Jacomb  
D.T.D. Hughes  
T. Connors

H.P. Lambert  
P. Turner  
A.M. Geddes  
D. Armitage  
D. Crowther  
D.S. Reeves  
R.E.O. Williams

## *International Society of Chemotherapy Executive - to July 1975*

P. Malek  
C. Grassi  
G.H. Werner

H.P. Kuemmerle  
Z. Modr  
K.H. Spitzzy  
P. Rentchnick

H. Ericsson  
G.M. Savage  
H. Umezawa

## Preface

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, penicillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, especially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tuberculosis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods.

From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of current progress in chemotherapy.

We thank the authors of these communications for their cooperation in enabling the Proceedings to be available at the earliest possible date. The method of preparation does not allow for uniformity of typefaces and presentation of the material and we hope that the blemishes of language and typographical errors do not detract from the understanding of the reader and the importance of the Proceedings.

K. HELLMANN, Imperial Cancer Research Fund  
A. M. GEDDES, East Birmingham Hospital  
J. D. WILLIAMS, The London Hospital Medical College

## Contents

Singapore Study of Intermittent Rifampicin Plus Isoniazid for Pulmonary Tuberculosis . . . . .	1
S. C. Poh	
Adverse Reactions to Intermittent Rifampicin . . . . .	9
D. J. Girling	
Choice of Drugs for Short-Course Chemotherapy . . . . .	17
D. A. Mitchison	
Short-Course Chemotherapy in Pulmonary Tuberculosis . . . . .	25
J. H. Angel	
Hong Kong Study of 6- and 9-Month Regimens of Daily and Intermittent Streptomycin, Isoniazid and Pyrazinamide for Pulmonary Tuberculosis . . . . .	35
M. Gabriel	
Structure-Activity Study on the Kasugamycin Family . . . . .	43
M. Hori, K. Suzukake, Y. Uehara, and H. Umezawa	
Experimental Data on the Antimycobacterial Activity of Isoprodian® . . . . .	47
R. Urbanczik	
Preliminary Experiences with Isoprodian® in the Treatment of Pulmonary Tuberculosis . . . . .	53
H. Blaha and W. Müller	
Comparative Study of the Inactivation of Isoniazid in Africans and Europeans . . . . .	59
E. Bergogne-Berezin and J. Modai	
Bioavailability of Rimactazid . . . . .	63
R. L. Parsons, G. M. Hossack, P. F. G. Boon, and D. M. Burley	



Rate of Sterilization of Sputum from Patients with Pulmonary Tuberculosis . . . . .	73
G. L. Hobby, H. W. Harris, C. Felton, and J. Edsall	
Re-treatment of Chronic Pulmonary Tuberculosis with Low and High Dosage Rifampicin Regimens in the Continuation Intermittent Phase (A Con- trolled Comparison Study) . . . . .	75
M. Zierski, E. Bek, J. Marcinia, and B. Szelagowicz	
Incidence of Drug Resistance on the Mycobacterial Strains Isolated from Treated and Untreated Patients . . . . .	81
J. A. Garcia, M. C. Saenz, J. Prieto, and F. Martin	
Intrauterine Administration of Streptomycin for Genital Tuberculosis . . . . .	87
G. Franz, M. Kaether, and R. Reimann	
Genetics of Low-Level Antibiotic Resistance in <u>Neisseria gonorrhoeae</u> . . . . .	91
P. F. Sparling, F. A. Sarubbi, Jr., and E. Blackman	
A Double-Blind Placebo-Controlled Trial of Minocycline in the Treatment of Non-Specific Urethritis . . . . .	97
M. J. Prentice, D. Taylor-Robinson, and G. W. Csonka	
Epidemiology and Etiology of Nongonococcal Urethritis in Men . . . . .	103
K. K. Holmes, W. O. Harrison, R. Hooper, and E. R. Alexander	
Surface Structures and Antibiotic Targets in the Gonococcus . . . . .	111
M. R. J. Salton, K. S. Kim, R. Davis, and K. Y. Cho	
Evaluation of the Ames <u>Neisseria gonorrhoeae</u> Culture System . . . . .	121
G. W. Csonka and S. H. Qureshi	
Treatment of Gonorrhoeae with "Gonococktail," A Single Dose of Ampicillin Plus Probenicid . . . . .	125
A. Lassus, O.-V. Renkonen, and R. Suhonen	
Treatment of Uncomplicated Gonorrhoeae with a Single Dose of Amoxycillin . . . . .	127
Al Lassus, O.-V. Renkonen, and T. Rostila	

Tetracycline in Treatment of Mycoplasma-Induced Prostato-Urethritis . . . . .	133
A. Hofstetter, H. Blenk, and R. Rangoonwala	
Assessment of Mycoplasmas and Infertility and the Effect of Doxycycline . . . . .	137
G. L. Ridgway, V. Little, E. Radwanska, and G. I. M. Swyer	
Oral, Vaginal, and Combined Orovaginal Therapy of Mycoplasmosis Urogenitalis . . . . .	143
E. R. Weissenbacher	
A Clinical Trial of Tinidazole in Uro-Genital Trichomoniasis . . . . .	149
M. Levrier	
Trichomonas Vaginitis and Its Treatment with Tinidazole . . .	155
P. E. R. Rhemrev and F. Kosasih	
The Problem of Trichomoniasis Vaginalis in Children . . . . .	161
E. Soyka	
Oral Treatment of Vaginal Trichomoniasis with Ornidazole, a Derivative of Metronidazole . . . . .	169
B. Rubio-Lotvin	
SPA-S-222, A New Oral Derivative for Short-Term Treatment of Vaginal Trichomoniasis . . . . .	175
R. Pellegrini and S. Fanciulli	
Short-Term Therapy of Urogenital Trichomoniasis with a New Nitroimidazole Derivative (Ornidazole/Tiberal Roche) . . . . .	179
S. Granitzka	
Rationale for Controlling the Emergence of Drug Resistance . .	185
E. J. L. Lowbury	
Mechanism of the Inhibitory Effect of Oxacillin on the Beta-Lactamase of <u>Bacillus cereus</u> . . . . .	199
J. Erdei, F. Hernádi, Cs. Jászberényi, T. Gunda, and G. Szabó	
Mode of Action of Chemotherapeutic Agents Against Bacteria Growing in a Continuous Flow Culture with Special Reference to the Anti-Bacterial Effect of Cephalothin, Erythromycin, and Kanamycin . . . . .	205
H. Otaya, A. Ozawa, and J. Goto	

Mode of Action of Flucytosine in <i>Aspergillus</i> Species . . . . .	211
G. Wagner and S. Shadomy	
Action of Polyene Macrolide Antibiotics on Protoplast Type L-Form of <i>E. Coli</i> . . . . .	217
I. Haupt, H. Thrum, E. Schuhmann, and R. Geuther	
Relationships between Inhibition of Nucleic Acid Synthesis and Competence in <i>B. subtilis</i> . . . . .	223
M. T. Pérez-Ureña, E. Garcia, M. Espinosa, and A. Portoles	
<sup>14</sup> C-Phenyl-Alanine Incorporation in the Presence of Several Antibiotics on <i>B. subtilis</i> Transfection . . . . .	229
A. Portoles, M. Espinosa, E. Garcia, and M. T. Pérez-Ureña	
Irreversible Inactivation of Ribosomes by Antibiotics . . . . .	235
C. Coutsogeorgopoulos	
Theoretical Basis of Antibiotic Combinations . . . . .	241
M. de M. Pinto-Ribeiro	
Antibiotic Sensitivity of <i>Haemophilus influenzae</i> . . . . .	247
P. Cavanagh, S. Kattan, and R. B. Sykes	
Drug Sensitivity Pattern of Gram-Negative Rod . . . . .	251
F. Matsumoto, Y. Ueda, M. Ohmori, and K. Shiba	
Pathogens, Isolated from Patients in Intensive Care Units and Their Surroundings with Regard to Their Antibiotic Susceptibility . . . . .	257
C. Krasemann, K. Botzenhart, and H. Rüden	
In Vitro Sensitivity of 10.610 Bacterial Strains to Trimethoprim-Sulfamethoxazole and Other Bacterial Agents . . . . .	265
C. Truffot, R. Bismuth, G. Pacaud, and J. Grosset	
The Prevalence of Ampicillin, Cephalosporin and Sulphonamide Resistance Amongst Urinary Tract Pathogens . . . . .	271
J. Andrews, M. J. Bywater, A. M. Emmerson, C. Keane, D. S. Reeves, and R. Wise	
Changes of Antimicrobial Susceptibility of Anaerobic Bacteria from Clinical Specimen . . . . .	279
J. Okada, T. Oguri, and N. Kosakai	

Bactericidal Effect of Cephalosporin Derivatives in Patient Material Containing Enterobacteriaceae Resistant to Ampicillin . . . . .	283
G. Lebek	
Antibacterial Activity of Rifampicin and Its Combinations Against Clinical Strains Isolated from Cases with Purulent-Inflammatory Processes . . . . .	291
I. P. Fomina, L. N. Samoiloova, L. E. Bodunkova, and S. M. Navashin	
Dynamics of Methicillin Resistant Staphylococci Under Effect of Eliminating Agents . . . . .	299
O. N. Speranskaya, I. P. Fomina, and V. S. Zueva	
Tetracycline Resistance in Pneumococci and Group A Streptococci: A Survey in the United Kingdom . . . . .	307
J. G. Kensit and W. Farrell	
Lysogeny of <i>Streptococcus pyogenes</i> and Transduction of Drug Resistance to Tetracycline, Chloramphenicol, and Macrolides Antibiotics with Phages Induced from Them . . . . .	313
K. Ubukata, M. Konno, and R. Fujii	
Comparative Activity of Tetracycline, Minocycline, Clomocycline and Methacycline Against Group A, B, C, and G $\beta$ -Haemolytic Streptococci . . . . .	319
R. Y. Cartwright and K. Korpala	
Cephalosporin-Tobramycin Activity Against Enterococci . . . . .	327
F. R. Fekety, B. Bruce, D. Turrell, C. Work, and J. Conway	
Gentamicin Resistant Gram-Negative-Bacilli at the Geriatric Hospital . . . . .	333
T. Inamatsu, K. Nakauchi, and K. Shimada	
Topical Chemoprophylaxis in Surgery . . . . .	339
A. V. Pollock	
Topical Chemotherapy and Prophylaxis in Thermal Injury . . . . .	351
R. B. Lindberg, B. A. Pruitt, Jr., and A. D. Mason, Jr.	
Antimicrobial Applications for Prophylaxis in the Newborn Hexachlorophane . . . . .	361
W. A. Gillespie, B. D. Corner, D. Burman, and V. G. Alder	

Chlorhexidine: Attempts to Detect Percutaneous Absorption in Man . . . . .	367
D. E. Case, J. McAinsh, A. Rushton, and M. J. Winrow	
The Disinfection of the Hands - Quantitative Aspects . . . . .	375
M. Rotter, H. Mittermayer, W. Koller, and G. Wewalka	
Topical Chemotherapy of Skin Disease . . . . .	381
A. Lyell	
Contamination of Antiseptics and Use of Preservatives . . . . .	389
D. A. Norton	
Chlorhexidine in the Control of Dental Plaque . . . . .	395
J. L. Honigman	
Soframycin Treatment of the Nasal Carrier after 14 Years . . . . .	403
B. C. Stratford and S. Dixon	
The Effect of Antimicrobial Agents on the Umbilical Cord . . . . .	415
R. H. George	
Meclocycline, an Antibiotic for Topical Use . . . . .	421
L. J. Bononi	
The Effectiveness of Povidone-Iodine, Savlon and Chlorhexidine as Pre-Operative Vaginal Disinfectants . . . . .	425
N. M. Duignan, J. D. Williams, and P. A. Lowe	
A Controlled Trial of Povidone-Iodine in the Prevention of Post-Operative Infection in Abdominal Wounds . . . . .	429
O. J. A. Gilmore and R. J. Sanderson	
Betadine . . . . .	435
P. R. Zellner and E. Metzger	
List of Contributors . . . . .	441

SINGAPORE STUDY OF INTERMITTENT RIFAMPICIN  
PLUS ISONIAZID FOR PULMONARY TUBERCULOSIS

S C Poh

Tan Tock Seng Hospital

Moulmein Road, Singapore 11

SUMMARY

In Singapore, 481 adult patients with newly diagnosed pulmonary tuberculosis were allocated at random to four regimens of intermittent rifampicin plus isoniazid. All patients received an initial two weeks of daily chemotherapy with streptomycin plus isoniazid plus rifampicin in standard daily dosages, followed by isoniazid 15 mg/kg body weight plus rifampicin 900 mg, both drugs twice a week (HR2 regimen) or once a week (HR1 regimen), or by isoniazid 15 mg/kg plus rifampicin 600 mg, both drugs twice a week (LR2 regimen) or once a week (LR1 regimen). All patients in addition received a supplementary daily capsule containing at random either rifampicin 25 mg or a matched placebo, to see if the daily supplement would reduce the incidence of adverse reactions to rifampicin.

The first 334 patients with fully drug-sensitive strains pretreatment were currently available for assessment at 12 months. Every single patient on the 2 twice-weekly regimens had a favourable bacteriological status at 12 months, as had 96% of the HR1 and 92% of the LR1 patients. Adverse reactions to intermittent rifampicin occurred in 26% of the HR1 patients, but on the other three regimens their incidence was low. In contrast, the incidence of rifampicin-dependent antibodies ranged from 21% (LR2) to 54% (HR1). The

incidence of adverse reactions and antibodies was unaffected by the rifampicin supplement.

## INTRODUCTION

At the time this study was planned, animal and in vitro experimental evidence suggested that in man both isoniazid and rifampicin should be suitable for intermittent chemotherapy (Dickinson et al. 1968; Grumbach et al. 1969; Verbist 1969; Dickinson and Mitchison 1970). In clinical practice, however, rifampicin in dosages of 900 to 1800 mg once a week and twice a week although effective, induced a high incidence of adverse reactions (Girling and Fox 1971; Poole et al. 1971; Aquinas et al. 1972; Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council 1974; Hong Kong Tuberculosis Treatment Services/British Medical Research Council 1974). The commonest of these was the 'flu' syndrome, a febrile reaction which came on one to two hours after a dose, lasted for several hours and was often associated with circulating rifampicin-dependent antibodies. It occurred more frequently during once weekly rifampicin treatment than during twice weekly treatment with the same dose size and it could sometimes be stopped simply by reducing the intermittent dose size. It did not occur during daily chemotherapy and was thought to be immunological in origin. Therefore, it was envisaged that a small daily dose of rifampicin given as a supplement to an intermittent regimen might prevent or reduce the incidence of adverse reactions and the development of rifampicin-dependent antibodies.

The present study was, therefore, designed to find out, first, whether intermittent rifampicin in lower dosages would be both therapeutically effective and of low toxicity when given with high dosage isoniazid, and secondly, whether adverse reactions and the development of antibodies could be reduced or avoided by giving a very small dose of rifampicin i.e. 25 mg daily in addition to the intermittent doses.

## CRITERIA OF ELIGIBILITY

Patients were admitted to the study if they had pulmonary tuberculosis, were aged 15 years or more, had received no previous antituberculosis chemotherapy and had sputum positive for tubercle bacilli on direct smear examination.

## REGIMENS STUDIED

All patients received an initial two weeks of daily chemotherapy with streptomycin plus isoniazid plus rifampicin in standard daily dosages. They were allocated at random to one of four intermittent continuation regimens as follows:

1. Rifampicin 900 mg twice weekly (HR2 regimen)
2. Rifampicin 900 mg once weekly (HR1 regimen)
3. Rifampicin 600 mg twice weekly (LR2 regimen)
4. Rifampicin 600 mg once weekly (LR1 regimen)

All patients on all four regimens received the same dose size of isoniazid, i.e. 15 mg per kg body weight per dose. In addition, all patients received a supplementary capsule every morning containing at random either rifampicin 25 mg or a matched placebo, so that this part of the study was conducted double blind.

Of the 481 patients admitted, the first 371 have been under observation in the study for 12 months or longer. Of these, 13 patients were excluded for pretreatment reasons which were bacteriological in all except two. Another 24 were excluded for reasons encountered during treatment, the majority because of alteration to chemotherapy for drug toxicity (9 patients) or intercurrent disease (7 patients), leaving 334 patients with fully drug-sensitive strains pretreatment in the main bacteriological comparison. These patients have all completed a year under study and the findings at one year are presented.

## PRETREATMENT COMPARISONS

The four regimens were similar in the pretreatment distribution of a number of factors including the following:

race (81% Chinese), age (average 43 years), sex (74% male), body weight (average 45 kg), radiological extent of disease (69% had moderate to gross disease), cavitation (55% had cavitation on a postero-anterior chest radiograph) and isoniazid inactivation rate (72% were rapid acetylators).



## THERAPEUTIC RESPONSE

## Patients with Fully Sensitive Strains Pretreatment

The single monthly culture results based on patients with fully drug sensitive strains pretreatment showed that the LR1 regimen lagged behind the other three regimens in the rate at which it produced sputum negativity in the early months of chemotherapy. At 12 months, all the HR2 patients had negative cultures, as did 90% of the HR1, 97% of the LR2 and 91% of the LR1 patients.

The bacteriological status at 12 months based on a total of 8 cultures at 10, 11 and 12 months is shown in Table 1. A favourable status was defined as all cultures negative or no more than 1 culture with a growth of 5 or more colonies. All patients on the two twice weekly regimens had a favourable status as did 96% of the HR1 and 92% of the LR1 patients. The therapeutic response on the twice-weekly regimens was significantly better than that on the once-weekly regimens ( $P = 0.005$ ), but the dose size had no significant effect.

Table 1

## BACTERIOLOGICAL STATUS AT 12 MONTHS

(based on 8 cultures at 10, 11 and 12 months)

	HR2		HR1		LR2		LR1	
	No.	%	No.	%	No.	%	No.	%
Patients assessed	85		78		87		84	
Favourable status	85	<u>100</u>	75	<u>96</u>	87	<u>100</u>	77	<u>92</u>

Ten patients (3 HR1, 7 LR1) had an unfavourable status. All 10 were excreting drug-resistant strains. Three of them developed isoniazid resistance followed by rifampicin resistance, 1 rifampicin resistance and then isoniazid resistance and another developed resistance to the two drugs at the same time. The remaining 5 developed resistance to isoniazid alone. All 10 were rapid acetylators of isoniazid.